STOCK TITAN

Hims & Hers Health (NYSE: HIMS) lifts 2026 outlook as Q2 revenue jumps 38%

(High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Hims & Hers Health, Inc. reported strong top-line growth for the quarter ended June 30, 2026, with revenue of $753.2 million, up 38% year-over-year. Subscribers reached 2.9 million, a 19% increase, and monthly revenue per average subscriber rose 21% to $92, reflecting higher monetization per customer. International expansion was a major driver, as Rest of the World revenue grew more than 17-fold to $131.4 million, aided by the close of the Eucalyptus acquisition, while U.S. revenue grew 16%.

Profitability and cash metrics deteriorated. Gross margin declined from 76% to 64%, and the company swung from $42.5 million net income to a $86.3 million net loss in the quarter. Adjusted EBITDA fell from $82.2 million to $60.3 million, and quarterly Free Cash Flow remained negative at $(68.2) million. Operating expenses rose sharply, including higher marketing, operations, technology, and general and administrative costs, with notable legal contingencies and acquisition-related charges.

The balance sheet expanded significantly following acquisitions and new financing. Total assets increased to $3.63 billion, with goodwill and intangibles over $1.5 billion. Convertible senior notes grew to $1.37 billion, and total liabilities more than doubled to $3.30 billion, while stockholders’ equity declined to $324.1 million. Despite these pressures, cash and cash equivalents rose to $609.8 million, supported by note issuance. Management raised full-year 2026 guidance to $3.1–$3.3 billion in revenue and $275–$325 million Adjusted EBITDA, implying an Adjusted EBITDA margin of 9–10%, and guided third-quarter 2026 revenue to $880–$900 million with Adjusted EBITDA of $75–$95 million.

Positive

  • Revenue accelerated 38% year-over-year to $753.2 million in Q2 2026, driven by 19% subscriber growth and higher monthly revenue per average subscriber.
  • International revenue grew more than 17-fold to $131.4 million in Q2 2026, significantly increasing geographic diversification alongside 16% U.S. revenue growth.
  • Management raised full-year 2026 revenue guidance to $3.1–$3.3 billion and boosted Adjusted EBITDA outlook to $275–$325 million, signaling confidence in continued scale.
  • Cash and cash equivalents increased to $609.8 million by June 30, 2026, supported by financing activities, providing a larger liquidity buffer for growth and integration.

Negative

  • Gross margin fell from 76% to 64% in Q2 2026, indicating significantly higher cost of revenue relative to sales.
  • Results shifted from $42.5 million net income to an $86.3 million net loss year-over-year in Q2 2026, reflecting higher expenses and charges.
  • Adjusted EBITDA declined from $82.2 million to $60.3 million in Q2 2026, and Free Cash Flow stayed negative at $(68.2) million, showing weaker underlying profitability.
  • Total liabilities more than doubled to $3.30 billion, including $1.37 billion of convertible senior notes, while stockholders’ equity fell to $324.1 million, increasing leverage.
  • Operating expenses rose sharply to $578.0 million in Q2 2026 from $389.5 million, driven by higher marketing, operations, technology, and general and administrative spending.

Insights

Analyzing...

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Revenue $753,214 thousand Three months ended June 30, 2026; 38% year-over-year increase
Q2 2026 Net (Loss) Income $(86,290) thousand Three months ended June 30, 2026; versus $42,505 thousand income in 2025
Q2 2026 Gross Margin 64% Three months ended June 30, 2026; down from 76% a year earlier
Q2 2026 Adjusted EBITDA $60,323 thousand Three months ended June 30, 2026; down from $82,236 thousand in 2025
Subscribers (end of period) 2,891 thousand End of Q2 2026; 19% year-over-year growth from 2,439 thousand
Cash and Cash Equivalents $609,811 thousand Balance at June 30, 2026 on condensed consolidated balance sheet
Convertible Senior Notes, Net $1,365,299 thousand Long-term liability as of June 30, 2026
2026 Revenue Guidance $3.1–$3.3 billion Full year 2026 outlook provided by management
Adjusted EBITDA financial
"Adjusted EBITDA was $60.3 million for the second quarter of 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Free Cash Flow financial
"Free Cash Flow was $(68.2) million for the second quarter of 2026"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
convertible senior notes financial
"Convertible senior notes, net | 1,365,299 | | | 972,580"
Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.
earn-out consideration financial
"Earn-out consideration | 81,364 | | | 50,632"
Earn-out consideration is money a buyer agrees to pay a seller after a takeover only if the acquired business meets specific future targets, such as revenue, profit, or product milestones. Think of it like a performance bonus that shifts some purchase price into the future; it matters to investors because it changes how much risk and potential value they should assign to a deal and can affect future cash flows, reported earnings, and ownership incentives.
GLP-1 medications medical
"providing access to branded GLP-1 medications, and offering access to compounded GLP-1"
GLP-1 medications are drugs that copy a natural gut hormone to help the body release insulin, lower blood sugar and reduce appetite by slowing how quickly the stomach empties. For investors, they matter because their strong clinical benefits have driven rapid sales growth, reshaped demand for diabetes and weight-loss treatments, and created regulatory, patent and pricing dynamics that can significantly affect healthcare companies’ revenues and profitability.
non-GAAP financial measures financial
"Non-GAAP Financial Measures In addition to our financial results"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Revenue $753,214 thousand in Q2 2026 38% increase year-over-year from $544,833 thousand
Net (Loss) Income $(86,290) thousand in Q2 2026 declined from $42,505 thousand net income year-over-year
Adjusted EBITDA $60,323 thousand in Q2 2026 down from $82,236 thousand year-over-year
Subscribers 2,891 thousand at end of Q2 2026 19% increase from 2,439 thousand year-over-year
Guidance

For Q3 2026, revenue guidance is $880–$900 million and Adjusted EBITDA $75–$95 million. For full-year 2026, revenue guidance is $3.1–$3.3 billion and Adjusted EBITDA $275–$325 million, implying 9–11% margins.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How did HIMS perform on revenue and subscriber growth in Q2 2026?

Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year. Subscribers reached 2.9 million, a 19% increase, while monthly revenue per average subscriber climbed 21% to $92, reflecting both user growth and higher monetization.

How fast did HIMS’s international business grow in Q2 2026?

International performance was strong, with Rest of the World revenue rising to $131.4 million, more than a 17-fold increase from $7.5 million in Q2 2025. This growth was supported by the Eucalyptus acquisition closed in June 2026.

What guidance did HIMS provide for Q3 and full-year 2026?

For Q3 2026, Hims & Hers expects revenue of $880–$900 million and Adjusted EBITDA of $75–$95 million. For full-year 2026, guidance is $3.1–$3.3 billion in revenue and $275–$325 million Adjusted EBITDA, implying 9–11% margins.

What is the balance sheet and debt position of HIMS as of June 30, 2026?

As of June 30, 2026, Hims & Hers had total assets of $3.63 billion and total liabilities of $3.30 billion, including $1.37 billion in convertible senior notes. Stockholders’ equity stood at $324.1 million, with cash and equivalents of $609.8 million.

How did HIMS’s cash flow and Free Cash Flow evolve in 2026 year-to-date?

For the first half of 2026, net cash provided by operating activities was $53.4 million, down from $90.0 million a year earlier. After capital expenditures and software investments, Free Cash Flow was $(15.2) million, compared with $(19.4) million in 2025.

What non-GAAP measures does HIMS emphasize, and why?

Hims & Hers highlights Adjusted EBITDA, Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Net (Loss) Income, and Free Cash Flow. Management uses these to evaluate ongoing operations, exclude certain non-recurring or non-cash items, and assess operating performance and liquidity alongside U.S. GAAP results.
0001773751false00017737512026-08-102026-08-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38986
98-1482650
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2269 Chestnut Street, #523
94123
San Francisco
,
California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code:  (415) 851-0195

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class
Trading symbol
Name of each exchange on which registered
Class A common stock, $0.0001 par value
HIMS
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 





Item 2.02.
Results of Operations and Financial Condition.
On August 10, 2026, Hims & Hers Health, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02.
The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.
Description
99.1
Press Release dated August 10, 2026
104
Cover Page Interactive Data file (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: August 10, 2026
By:
/s/ Oluyemi Okupe
Oluyemi Okupe
Chief Financial Officer
(Principal Financial Officer)




Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026

Subscribers grew to nearly 2.9 million, up 19% year-over-year in Q2 2026

Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million


SAN FRANCISCO, August 10, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026.

“Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care. We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive,” said Andrew Dudum, co-founder and CEO. “We have never been better positioned to move faster or go further than we are today. As we rebuild the consumer health experience from the ground up with a doctor-led AI clinical engine, the depth and breadth of our relationships with customers worldwide has never been greater. Every quarter, we raise the standard for what care should look like everywhere: high-quality, personal, and accessible.”

“Our second quarter results were defined by a significant re-acceleration in our growth profile and the continued expanding reach of our platform,” said Yemi Okupe, Chief Financial Officer. “Domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition in June. We expect our domestic business to continue accelerating through the second half of the year. This momentum, combined with the meaningful efficiencies we're generating from our investments in AI and technology, positions us to make access to high touch, comprehensive care more affordable for our customers while also significantly expanding our reach internationally. As a result, we are raising our 2026 revenue outlook and building increased conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.”






Key Business Metrics
(In Thousands, Except for Monthly Revenue per Average Subscriber, Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
% Change
2026
2025
% Change
Subscribers (end of period)
2,891 
2,439 
19 
%
2,891 
2,439 
19 
%
Monthly Revenue per Average Subscriber
$
92 
$
76 
21 
%
$
84 
$
81 
%

Revenue
(In Thousands, Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,

2026
2025
% Change
2026
2025
% Change
United States Revenue
$
621,830 
$
537,286 
16 
%
$
1,151,739 
$
1,115,978 
%
Rest of the World Revenue
131,384 
7,547 
1,641 
%
209,579 
14,865 
1,310 
%
Total revenue
$
753,214 
$
544,833 
38 
%
$
1,361,318 
$
1,130,843 
20 
%

Second Quarter 2026 Financial Highlights
Revenue was $753.2 million for the second quarter of 2026 compared to $544.8 million for the second quarter of 2025, an increase of 38% year-over-year.
Gross margin was 64% for the second quarter of 2026 compared to 76% for the second quarter of 2025.
Net loss was $86.3 million for the second quarter of 2026 compared to net income of $42.5 million for the second quarter of 2025.
Adjusted EBITDA was $60.3 million for the second quarter of 2026 compared to $82.2 million for the second quarter of 2025.
Net cash (used in) operating activities was $(35.9) million for the second quarter of 2026 compared to $(19.1) million for the second quarter of 2025.
Free Cash Flow was $(68.2) million for the second quarter of 2026 compared to $(69.4) million for the second quarter of 2025.

Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net (loss) income and net cash (used in) provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers is providing the following guidance:

For the third quarter 2026, we expect:
Revenue of $880 million to $900 million.
Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.

For the full year 2026, we expect:
Revenue of $3.1 billion to $3.3 billion.
Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.




We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the second quarter 2026 results on August 10, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants, and referencing conference ID #782 611 911. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit investors.hims.com.




Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions; changes in our product or offering mix, and the timing and market acceptance of any new products or offerings; the timing and anticipated effect of any pending or recently completed acquisitions; the success and utility of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of August 10, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most



recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, membership-based access, post-consultation service support, and delivery of laboratory testing results, as applicable. Our online sales are net of refunds, credits, and chargebacks, and include revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. A substantial majority of our online sales are subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. This revenue also includes sales from customers who have made one-time purchases.

“United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

“Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

“Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.




CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share and Per Share Data, Unaudited)
June 30, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
609,811 
$
228,616 
Short-term available-for-sale investments
231,237 
348,876 
Receivables, net
375,291 
32,149 
Inventory
87,781 
80,128 
Prepaid expenses and other current assets
80,493 
77,869 
Total current assets
1,384,613 
767,638 
Long-term available-for-sale investments
— 
351,263 
Goodwill
1,101,720 
278,325 
Property, equipment, and software, net
364,215 
311,930 
Intangible assets, net
422,809 
196,116 
Operating lease right-of-use assets
165,565 
137,046 
Deferred tax assets, net
111,578 
82,707 
Other long-term assets
78,314 
29,680 
Total assets
$
3,628,814 
$
2,154,705 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$
501,297 
$
143,278 
Accrued liabilities
210,255 
77,039 
Deferred revenue
141,384 
127,160 
Deferred acquisition payable
537,381 
1,479 
Earn-out consideration
81,364 
50,632 
Operating lease liabilities
11,551 
4,843 
Total current liabilities
1,483,232 
404,431 
Convertible senior notes, net
1,365,299 
972,580 
Operating lease liabilities
169,389 
143,167 
Deferred acquisition payable
165,624 
5,484 
Earn-out consideration
81,600 
53,009 
Deferred tax liabilities, net
30,934 
28,856 
Other long-term liabilities
8,664 
6,250 
Total liabilities
3,304,742 
1,613,777 
Commitments and contingencies
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 224,920,310 and 218,867,898 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of June 30, 2026 and December 31, 2025
23 
23 
Additional paid-in capital
662,263 
652,383 
Accumulated other comprehensive (loss) income
(46,037)
2,294 
Accumulated deficit
(292,177)
(113,772)
Total stockholders' equity
324,072 
540,928 
Total liabilities and stockholders' equity
$
3,628,814 
$
2,154,705 



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(In Thousands, Except Share and Per Share Data, Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenue
$
753,214 
$
544,833 
$
1,361,318 
$
1,130,843 
Cost of revenue
272,411 
128,637 
483,728 
283,958 
Gross profit
480,803 
416,196 
877,590 
846,885 
Gross margin %
64 
%
76 
%
64 
%
75 
%
Operating expenses:(1)
Marketing
262,236 
217,862 
484,239 
449,097 
Operations and support
95,481 
66,490 
191,984 
129,523 
Technology and development
54,901 
37,848 
101,837 
67,762 
General and administrative
165,377 
67,273 
275,045 
115,883 
Total operating expenses
577,995 
389,473 
1,053,105 
762,265 
(Loss) income from operations
(97,192)
26,723 
(175,515)
84,620 
Other income (expense):
Change in fair value of equity securities
4,737 
— 
(4,945)
— 
Change in fair value of liabilities
(4,223)
— 
(21,869)
— 
Other income, net
4,045 
6,130 
8,145 
8,728 
Total other income (expense), net
4,559 
6,130 
(18,669)
8,728 
(Loss) income before income taxes
(92,633)
32,853 
(194,184)
93,348 
Benefit from (provision for) income taxes
6,343 
9,652 
15,779 
(1,358)
Net (loss) income
(86,290)
42,505 
(178,405)
91,990 
Other comprehensive (loss) income
(41,632)
986 
(48,331)
1,146 
Total comprehensive (loss) income
$
(127,922)
$
43,491 
$
(226,736)
$
93,136 
Net (loss) income per share attributable to common stockholders:
Basic
$
(0.37)
$
0.19 
$
(0.78)
$
0.41 
Diluted
$
(0.37)
$
0.17 
$
(0.78)
$
0.37 
Weighted average shares outstanding:
Basic
231,746,126 
224,373,375 
230,061,076 
223,187,936 
Diluted
231,746,126 
256,779,292 
230,061,076 
251,894,929 
______________ 
(1)Includes stock-based compensation expense as follows (in thousands):

Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Marketing
$
3,004 
$
3,435 
$
5,819 
$
6,209 
Operations and support
7,016 
4,579 
13,129 
7,585 
Technology and development
6,645 
5,247 
12,635 
9,292 
General and administrative
25,451 
22,465 
47,395 
37,498 
Total stock-based compensation expense
$
42,116 
$
35,726 
$
78,978 
$
60,584 




CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands, Unaudited)
Six Months Ended June 30,
2026
2025
Operating activities
Net (loss) income
$
(178,405)
$
91,990 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization
51,430 
18,741 
Stock-based compensation
78,978 
60,584 
Change in fair value of equity securities
4,945 
— 
Change in fair value of liabilities
21,869 
— 
Net accretion on securities
(338)
(1,060)
Benefit from deferred taxes
(23,338)
(10,346)
Impairment of long-lived assets
1,148 
— 
Amortization of debt discount and issuance costs
3,656 
1,047 
Non-cash operating lease cost
9,482 
4,594 
Non-cash acquisition-related costs
21,311 
2,985 
Non-cash restructuring and other related charges included within cost of revenue
28,462 
— 
Non-cash other
2,511 
(1,315)
Changes in operating assets and liabilities:
Receivables, net
(328,987)
(654)
Inventory
(14,255)
(77,373)
Prepaid expenses and other current assets
80 
(37,427)
Other long-term assets
(30,553)
(10)
Accounts payable
323,795 
5,146 
Accrued liabilities
89,526 
11,737 
Deferred revenue
2,960 
23,132 
Earn-out consideration
(7,058)
— 
Deferred acquisition payable
472 
— 
Operating lease liabilities
(4,894)
(1,798)
Other long-term liabilities
620 
— 
Net cash provided by operating activities
53,417 
89,973 
Investing activities
Maturities of available-for-sale investments
116,232 
60,569 
Proceeds from sales of available-for-sale investments
350,762 
— 
Purchases of property, equipment, and intangible assets
(55,770)
(101,392)
Investment in website development and internal-use software
(12,808)
(7,961)
Acquisition of businesses, net of cash acquired
(318,108)
(5,100)
Purchases of equity securities
(11,217)
— 
Net cash provided by (used in) investing activities
69,091 
(53,884)
Financing activities
Proceeds from issuance of convertible senior notes, net of debt discount
390,425 
970,000 
Purchases of capped calls related to convertible senior notes
(36,748)
(47,800)
Proceeds from exercise of vested stock options
13,030 
6,497 
Payments for taxes related to net share settlement of equity awards
(62,324)
(62,475)
Proceeds from employee stock purchase plan
3,846 
2,970 
Payments for acquisition-related earn-out consideration
(43,682)
— 
Payments for debt issuance costs
(671)
(3,041)
Net cash provided by financing activities
263,876 
866,151 
Foreign currency effect on cash and cash equivalents
(5,189)
1,270 
Increase in cash, cash equivalents, and restricted cash
381,195 
903,510 
Cash, cash equivalents, and restricted cash at beginning of period
228,616 
221,440 
Cash, cash equivalents, and restricted cash at end of period
$
609,811 
$
1,124,950 
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents
$
609,811 
$
1,124,582 
Restricted cash
— 
368 
Total cash, cash equivalents, and restricted cash
$
609,811 
$
1,124,950 
Supplemental disclosures of cash flow information
Cash (received) paid for taxes, net of refunds
$
(2,663)
$
23,047 
Cash paid for interest
1,735 
— 
Non-cash investing and financing activities
Purchases of property, equipment, and intangible assets included in accounts payable and accrued liabilities
$
16,666 
$
16,954 
Right-of-use asset obtained in exchange for lease liability
25,681 
63,434 
Contingent and deferred consideration and liabilities assumed in connection with acquisition of businesses
886,287 
— 
Deferred debt issuance costs included in accounts payable and accrued liabilities
— 
249 
Issuance of common stock in connection with asset acquisition
— 
12,760 
Common stock to be issued for asset acquisition indemnification holdback
— 
6,380 



Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure), each as defined below. We also present Adjusted Gross Profit, Adjusted Marketing, Adjusted Operations and support, Adjusted Technology and development, Adjusted General and administrative (collectively, Adjusted Operating Expenses), and Adjusted Net (Loss) Income (each of which are non-GAAP financial measures). We use Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net (loss) income before legal contingencies that are considered non-recurring, stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), restructuring and other related charges that are considered non-recurring, change in fair value of liabilities, payroll tax expense related to stock-based compensation, impairment of long-lived assets, interest income and expense, net, change in fair value of equity securities, and income taxes. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

In the first quarter of 2026, we announced a strategic shift for our United States weight loss offering ("2026 US WL Announcement"). As a result, we evolved our United States weight loss offering to match our global approach towards providing access to branded GLP-1 medications, and offering access to compounded GLP-1 medications through our platform on a limited scale. In connection with the strategic shift, we revised our definition of Adjusted EBITDA to include restructuring and other related charges that are considered non-recurring, as we believe these costs are distinguishable from ongoing operating costs and do not reflect current or expected performance of our ongoing operations. These costs consist of inventory write-downs, third-party costs, and non-recurring employee compensation charges, all of which were incurred directly as a result of the 2026 US WL Announcement. Additional restructuring and other related charges were incurred in the second quarter of 2026, and to the extent that we incur further restructuring and other related charges in connection with the 2026 US WL Announcement in future periods,



these costs will be presented consistently with our current presentation. As we did not record any non-recurring restructuring and other related charges in prior years, prior period disclosures were not impacted.

In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.

Net (Loss) Income to Adjusted EBITDA Reconciliation
(In Thousands, Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenue
$
753,214 
$
544,833 
$
1,361,318 
$
1,130,843 
Net (loss) income
(86,290)
42,505 
(178,405)
91,990 
Legal contingencies
47,500 
— 
62,500 
— 
Stock-based compensation
42,116 
35,726 
78,978 
60,584 
Depreciation and amortization
29,477 
10,465 
51,430 
18,741 
Acquisition and transaction-related costs
28,835 
6,231 
42,201 
6,255 
Restructuring and other related charges
4,626 
— 
38,114 
— 
Change in fair value of liabilities
4,223 
— 
21,869 
— 
Payroll tax expense related to stock-based compensation
2,022 
3,078 
4,889 
3,078 
Impairment of long-lived assets
1,148 
— 
1,148 
— 
Interest income and expense, net
(2,254)
(6,117)
(7,287)
(8,713)
Change in fair value of equity securities
(4,737)
— 
4,945 
— 
(Benefit from) provision for income taxes
(6,343)
(9,652)
(15,779)
1,358 
Adjusted EBITDA
$
60,323 
$
82,236 
$
104,603 
$
173,293 
Net (loss) income as a % of revenue
(11)
%
%
(13)
%
%
Adjusted EBITDA margin
%
15 
%
%
15 
%

Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. “Free Cash Flow” is defined as net cash (used in) provided by operating activities, less



purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash (used in) provided by operating activities and other U.S. GAAP results.

Net Cash (Used In) Provided By Operating Activities to Free Cash Flow Reconciliation
(In Thousands, Unaudited)

Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Net cash (used in) provided by operating activities
$
(35,939)
$
(19,117)
$
53,417 
$
89,973 
Purchases of property, equipment, and intangible assets in investing activities
(25,926)
(46,065)
(55,770)
(101,392)
Investment in website development and internal-use software in investing activities
(6,328)
(4,250)
(12,808)
(7,961)
Free Cash Flow
$
(68,193)
$
(69,432)
$
(15,161)
$
(19,380)

Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income are key performance measures that our management uses to assess our operating performance. Because Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes. “Adjusted Gross Profit” is defined as gross profit adjusted for restructuring and other related charges included within cost of revenue. “Adjusted gross margin” is defined as Adjusted Gross Profit divided by revenue. “Adjusted Marketing” is defined as marketing expense adjusted for stock-based compensation. “Adjusted Operations and support” is defined as operations and support expense adjusted for stock-based compensation and restructuring and other related charges included within operating expenses. “Adjusted Technology and development” is defined as technology and development expense adjusted for stock-based compensation. “Adjusted General and administrative” is defined as general and administrative expense adjusted for legal contingencies, acquisition and transaction-related costs, and stock-based compensation. “Adjusted Net (Loss) Income” represents Net (Loss) Income adjusted for legal contingencies, acquisition and transaction-related costs, and restructuring and other related charges, net of related tax effects.

Some of the limitations of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income include that they omit certain costs and charges, and therefore do not reflect all expenses that impact the corresponding U.S. GAAP results. In evaluating Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income, you should be aware that in the future we may incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.




Gross Profit to Adjusted Gross Profit Reconciliation
(In Thousands, Unaudited)

Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenue
$
753,214 
$
544,833 
$
1,361,318 
$
1,130,843 
Gross Profit
480,803 
416,196 
877,590 
846,885 
Restructuring and other related charges included within cost of revenue
— 
— 
28,462 
— 
Adjusted Gross Profit
$
480,803 
$
416,196 
$
906,052 
$
846,885 
Gross margin %
64 
%
76 
%
64 
%
75 
%
Adjusted gross margin %
64 
%
76 
%
67 
%
75 
%

Operating Expenses to Adjusted Operating Expenses Reconciliation
(In Thousands, Unaudited)

Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Marketing
$
262,236 
$
217,862 
$
484,239 
$
449,097 
Stock-based compensation
(3,004)
(3,435)
(5,819)
(6,209)
Adjusted Marketing
$
259,232 
$
214,427 
$
478,420 
$
442,888 
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Operations and support
$
95,481 
$
66,490 
$
191,984 
$
129,523 
Stock-based compensation
(7,016)
(4,579)
(13,129)
(7,585)
Restructuring and other related charges included within operating expenses
(4,626)
— 
(9,652)
— 
Adjusted Operations and support
$
83,839 
$
61,911 
$
169,203 
$
121,938 
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Technology and development
$
54,901 
$
37,848 
$
101,837 
$
67,762 
Stock-based compensation
(6,645)
(5,247)
(12,635)
(9,292)
Adjusted Technology and development
$
48,256 
$
32,601 
$
89,202 
$
58,470 
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
General and administrative
$
165,377 
$
67,273 
$
275,045 
$
115,883 
Legal contingencies
(47,500)
— 
(62,500)
— 
Acquisition and transaction-related costs
(28,835)
(6,231)
(42,201)
(6,255)
Stock-based compensation
(25,451)
(22,465)
(47,395)
(37,498)
Adjusted General and administrative
$
63,591 
$
38,577 
$
122,949 
$
72,130 




Net (Loss) Income to Adjusted Net (Loss) Income Reconciliation
(In Thousands, Unaudited)

Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Net (loss) income
$
(86,290)
$
42,505 
$
(178,405)
$
91,990 
Legal contingencies
47,500 
— 
62,500 
— 
Acquisition and transaction-related costs
28,835 
6,231 
42,201 
6,255 
Restructuring and other related charges
4,626 
— 
38,114 
— 
Tax effects of adjustments
(15,423)
— 
(28,763)
— 
Adjusted Net (Loss) Income
$
(20,752)
$
48,736 
$
(64,353)
$
98,245 

Contacts:
Investor Relations
Bill Newby
Investors@forhims.com

Media Relations
Abby Reisinger-Moley
Press@forhims.com

Filing Exhibits & Attachments

4 documents